
References

Atwood CW Jr, McCrory D, Garcia JG et al., Pulmonary artery hypertension and sleep-disordered breathing: ACCP evidence-based clinical practice guidelines. *Chest* 2004; 126 (1 Suppl.): 72S–7.).

A. Giaid and D. Saleh, Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension, *N Engl J Med* 333 (1995), pp. 214–221) .

A.L. Burnett, Phosphodiesterase 5 mechanisms and therapeutic applications, *Am J Cardiol* **96** (2005), pp. 29M–31M

A.L. Burnett, Phosphodiesterase 5 mechanisms and therapeutic applications, *Am J Cardiol* 96 (2005), pp. 29M–31M.

Agostino PV, Plano SA, Golombek DA. "Sildenafil accelerates reentrainment of circadian rhythms after advancing light schedules". *Proc. Natl. Acad. Sci. U.S.A.* 104 (23): 9834–9. doi:10.1073/pnas.0703388104. PMID 17519328. (2007)

Alert for Healthcare Professionals: Sildenafil citrate (marketed as Viagra)". **United States Food and Drug Administration** (July 2005).

American College of Cardiology; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. *Circulation.* 112: 2005; e154-e235.

American College of Sports Medicine. ACSM's guidelines for exercise testing and prescription, 6th ed. Baltimore, MD: Williams & Wilkins; 2000. p. xvi.

American Heart Association. Heart Disease and Stroke Statistics-2004 Update.

Dallas Tex.: American Heart Association 2003. JAMA. 2006;296:2209-2216

Andersen KL, Shepard RJ, Denolin H, et al . . Fundamentals of exercise testing.

Geneva, Switzerland: World Health Organization; 1971. p. 138

Anderson TJ, Elstein E, Haber H et al., Comparative study of ACE inhibition, angiotensin II antagonism and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35: 60–6.].

Arcasoy SM, Christie JD, Ferrari VA et al., Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167: 735–40.).

ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108: 1146–62.

Aubetawe Bro Morgannwg University NHS Trust . "Research at ABM". Retrieved on 2008-08-06.

Auger WR, Kim NH, Kerr KM et al., Chronic thromboembolic pulmonary hypertension. Clin Chest Med 2007; 28: 255–69.).

Aymong ED, Curtis MJ, Youssef M et al., Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002; 105: 2981–5.].

B.K.S. Sastry DM C. Narasimhan DM N.Krishna Reddy DM and B.Soma Raju DM in 2003.

Badgett RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? *Journal of the American Medical Association* 1997;277:1712–9.).

Badgett RG, Mulrow CD, Otto PM, Ramirez G. How well can the chest radiograph diagnose left ventricular dysfunction? *Journal of General Internal Medicine* 1996;11:625–34.).

Baldasseroni S; Opasich C; Gorini M; Lucci D, et al (2002). "Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure.". *American Heart Journal* 143 (3): 398–405 ¹.

Barst RJ, McGoon M, Torbicki A., et al., Diagnosis and differential assessment of pulmonary arterial hypertension. *J Am Coll Cardiol* 2004; 43 (12 Suppl. S): 40S–7.

Bellis M. "Viagra, the patenting of an aphrodisiac". *About.com*.

Bocchi EA, Guimarães G, Mocelin A, et al ., Sildenafil effects on exercise neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomised study followed by a prospective treatment for erectile dysfunction. *Circulation* 2002; 106:1097–103. 2348 Guazzi et al. *JACC Vol. 44, No. 12, 2004 Sildenafil and Exercise Capacity in Heart Failure* December 21, 2004:2339–48).

Brecker SJ, Gibbs JS, Fox KM et al., Comparison of Doppler derived haemodynamic variables and simultaneous high fidelity pressure measurements in severe pulmonary hypertension. *Br Heart J* 1994; 72: 384–9.

Brown JW, Heath D, Whitaker W. Idiopathic pulmonary hypertension. *Br Heart J* 1957; 19: 83–92.).

Buchfuhrer MJ, Hansen JE, Robinson TE, et al ., Optimizing the exercise protocol for cardiopulmonary assessment. *J Appl Physiol* 1983;55:1558–1564

Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. *Circ Res* 2000; 87: 840–4].

Ceriello A, Falletti E, Bortolotti N et al., Increased circulating ICAM-1 levels in Type-2 diabetic patients: the possible role of metabolic control and oxidative stress. *Metabolism* 1996; 45: 498–501.].

Cheitlin MD, Armstrong WF, Aurigemma GP et al., ACC/AHA/ ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). *Circulation* 2003; 108: 1146–62.

Cheitlin MD, Hutter AM Jr, Brindis RG, et al.,"ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association". *Journal of the American College of Cardiology* 33 (1): 273–82. doi:10.1016/S0735-1097(98)00656-1. PMID 9935041.

Chen WJ, Chen JJ, Lin SC et al., Detection of cardiovascular shunts by transesophageal echocardiography in patients with pulmonary hypertension of unexplained cause. *Chest* 1995; 107: 8–13.).

Committee on Exercise Testing. ACC/AHA Guidelines for Exercise Testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 1997;30:260–311.)

Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of ED in patients with ischemic heart disease. *Am J Cardiol* 1999;83 (Suppl 5A):29C–34C.).

Cooke JP, Tsao PS: Go with the flow. *Circulation* 2001, 103:2773-2775) .

Cool CD, Rai PR, Yeager ME, et al., "Expression of human herpesvirus 8 in primary pulmonary hypertension". *N. Engl. J. Med.* 349 (12): 1113–22. ¹ (2003).

Cooper LT, Baughman KL, Feldman AM. , et al., The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. *Eur Heart J* 2007;28:3076-3093. 68. Jaarsma T, Stromberg A, Martensson J, Dracup K.).

Corretti MC, Anderson TJ, Benjjamiin EJ et al., Guidelines for the ultrasound assessment off endothelial-dependent flow-mediated vasodilation of the brachial artery. *J Am Coll Cardiol* 2002; 39: 257–65.].

Craig I. Bradbury I, Cummins E, Downie S, et al., The use of B-type natriuretic peptides (BNP and NT-proBNP) in the investigation of patients with suspected heart failure. Glasgow: NHS Quality Improvement Scotland; 2005.

Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis, 6th ed. Boston: Little, Brown and co, 1964;114.

D.M. Mancini and C.C. Lang, Alterations in pulmonary and diaphragmatic function in heart failure. In: D.L. Man, Editor, *Heart failure: a companion to Braunwald's heart disease* (1st ed.), Saunders, Philadelphia (2004), pp. 304–305.

D'Alonzo GE, Barst RJ, Ayres SM et al., Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med* 1991; 115: 343–9.).

D'Alonzo GE, Gianotti LA, Pohil RL et al., Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. *Chest* 1987; 92: 57–62.

Da Ros R, Quagliario L, Gasparini D et al., Nitrotyrosine in peripheral vascular disease. *J Thromb Haemost* 2003; 1: 382–3.].

Damy T, Ratajczak P, Shah AM, et al., Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. *Lancet* 2004; 363:1365.¹.

Davi G, Ciabattoni G, Consoli A et al., In vivo formation of 8-iso-prostaglandin F₂alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. *Circulation* 1999; 99: 224–9.].

Dell'Italia L, Sabri A: Activation of the renin-angiotensin system in hypertrophy and heart failure. In: Mann DL, ed. *Heart Failure: A Companion to Braunwald's Heart Disease*, Philadelphia: Saunders; 2004:129-143.¹.

Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. *Am J Med* 1951; 11:686–705.).

Edimar Alcides Bocchi, Guilherme Guimarães, Amilcar Mocelin, Et al ., Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectil Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction. *Circulation* ,106;1097-1103 originally published online Aug 5, 2002;

E.A. Bocchi, G. Guimarães, A. Mocelin, et al ., Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure, *Circulation* 106 (2002), pp. 1097–1103) .

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. *European Heart Journal* 2008. 29 p.2390) .

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. *European Heart Journal* 2008. 29 p.2392

Esper RJ, Vilarinho JO: La disfunción endotelial. In *Aterotrombosis en el tercer milenio*. Edited by: Esper RJ. Prous Sciences, Barcelona; 2004:49-83.].

Fagenholz PJ, Gutman JA, Murray AF, et al ., "Treatment of high altitude pulmonary edema at 4240 m in Nepal". *High Alt. Med. Biol.* 8 (2): 139–46. doi:10.1089/ham.2007.1055. PMID 17584008.

FDA Announces Revisions to Labels for Cialis, Levitra and Viagra". Food and Drug Administration . Retrieved on 2007-12-08.

Feldman CL, Stone PH: Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque. *Curr Opin in Cardiol* 2000, 15:430-440.].

Ficht RM, Vergona R, Sullivan ME, et al ., Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. *Cardiovasc Res* 2001; 51: 351–8.].

Floras JS: Sympathetic activation in human heart failure: Diverse mechanisms, therapeutic opportunities. *Acta Physiol Scand* 2003; 177:391.¹

Fonarow GC, Abraham WT, Albert NM, et al., "Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings From OPTIMIZE-HF". *Arch. Intern. Med.* 168 (8): 847–85. **(April 2008)**.

Fuster V, Steele PM, Edwards WD et al., Primary pulmonary hypertension: natural history and the importance of thrombosis.

Fuster V, Steele PM, Edwards WD et al., Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation* 1984; 70: 580–7.).

G.D. Lewis, J. Lachmann, J. Camuso, et al., Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure, *Circulation* **115** (2007), pp. 59–66.

G.D. Lewis, R. Shah, K. Shahzad, et al., Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension, *Circulation* **116** (2007), pp. 1555–1562.

Gaine S. Pulmonary hypertension. *JAMA* 2000; 284: 3160–8.).

Gaine SP, Rubin LJ. Primary pulmonary hypertension. *Lancet* 1998; 352: 719–25.).

Gearing AJH, Newman W. Circulating adhesion molecules in disease. *Immunol Today* 1993; 14: 506–12. 75. Ceri.

Gladwin MT, Sachdev V, Jison ML, et al., . "Pulmonary hypertension as a risk factor for death in patients with sickle cell disease". *N. Engl. J. Med.* 350 (9): 886–95.¹. (2004)

Gokce N, Keaney JF Jr, Hunter LM et al., Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. *Circulation* 2002; 105: 1567–72.].

Gomez A, Bialostozky D, Zajarias A et al., Right ventricular ischemia in patients with primary pulmonary hypertension. *J Am Coll Cardiol* 2001; 38: 1137–42.)

Grieve DJ, Shah AM: Oxidative stress in heart failure. More than just damage. *Eur Heart J* 2003; 24:2161.

Grossman W, Barry WH. Cardiac catheterization. In: Braunwald E, ed. *Heart Disease a Textbook of Cardiovascular Medicine*. Philadelphia, PA: W.B. Saunders Company, 1988: 242–67.

Guazzi M, Agostoni P, Guazzi MD. Alveolar-capillary gas exchange and exercise performance in heart failure. *Am J Cardiol* 2001;88:39–44).

Guazzi M, Brambilla R, De Vita S, et al ., Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. *Am J Resp Crit Care Med* 2002;166:978–82.).

Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiological role. *Chest* 2003;124:1090 –102.).

Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 1995;26:1376-98.

Hatano S, Strasser R. Primary pulmonary hypertension. Geneva: World Health Organization.¹. (1975)

Haulica I, Petrescu G, Slatineanu SM, et al., New bioactive angiotensins formation pathways and functional involvements. *Rom J Intern Med* 2004; 42:27.

Hayaishi-Okano R, Yamasaki Y, Kajimoto Y et al., Association of NAD(P)H oxidase p22 phox gene variation with advanced carotid atherosclerosis in Japanese type 2 diabetes. *Diabetes Care* 2003; 26(2): 458–63.].

He J; Ogden LG; Bazzano LA; Vupputuri S, et al ., "Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study.". *Arch. Intern. Med.* 161 (7): 996–1002. (2001).

Hendel RC, Patel MR, Kramer CM, et al., appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of

Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology.) *Am Coll Cardiol* 2006;48:1475-1497.

Holvoet P, Harris TB, Tracy RP et al., Association of high coronary heart disease risk status with circulating oxidized LDL in the wellfunctioning elderly: findings from the Health, Aging, and Body Composition study. *Arterioscler Thromb Vasc Biol* 2003; 23: 1444–8.

Hunt SA, Baker DW, Chin MH, et al., ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *Circulation* 2001; 104:2996-3007.

Ischiropoulos H. Biological selectivity and functional aspects of protein tyrosine nitration. *Biochem Biophys Res Commun* 2003; 305: 776–83.].

J.J. Lepore, A. Maroo, L.M. Bigatello, et al., Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension, *Chest* 127 (2005), pp. 1647–1653.

J.P.J. Halcox, K.R.A. Nour, G. Zalos, et al., The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia, *J Am Coll Cardiol* **40** (2002), pp. 1232–1240

Jackson G, Benjamin N, Jackson N, et al., Effects of sildenafil citrate on human hemodynamics. *Am J Cardiol* 1999;83:13C–20C.).

jardinsTD , cardiopulmonary anatomy & physiology, 2nd edition publishers inc.USA 1993.

Johnson RL Jr. Gas exchange efficiency in congestive heart failure II. *Circulation* 2001;103:916–8.

Johnstone DE, Abdulla A, Arnold JM et al., Diagnosis and management of heart failure. Canadian Cardiovascular Society. Canadian Journal of Cardiology 1994;10: 613–31.) .

Jones CJH, Kuo L, Davis MJ, et al ., Role of nitric oxide in coronary microvascular responses to adenosine and increased metabolic demand. Circulation 1996, 91:1807-1813.).

Jones NL. Clinical exercise testing, 4th ed. 1997, Philadelphia: W. B. Saunders; p. xi

Jourdain P, Jondeau G, Funck F, et al ., Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.) Am Coll Cardiol 2007;49:1733-1739.).

Metra M, Nodari S, Parrinello G, et al ., . The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T Eur) Heart Fail 2007;9: 776-786.).

Kacimi R, Long CS, Karliner JS: Chronic hypoxia modulates the interleukin-1 β -stimulated inducible nitric oxide synthase pathway in cardiac myocytes. Circulation 1997, 96:1937-1943.

Katz SD, Balidemaj K, Homma S, et al ., Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845–51.

Katz SD, Krum H, Khan T, et al ., Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996;28:585–90.).

Kawano H, Do YS, Kawano Y, et al ., Angiotensin II has multiple profibrotic effects in human cardiac fibroblast. Circulation 2000, 101:1130-1137.).

Kim WR, Krowka MJ, Plevak DJ et al., Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. *Liver Transpl* 2000; 6: 453–8.

Kling J "From hypertension to angina to Viagra". *Mod Drug Discov* 1: 31–38. (1998).

Kloner RA "Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions". *Am J Cardiol* 96 (12B): 42M–46M. doi:10.1016/j.amjcard.2005.07.011. PMID 16387566. (2005).

Kloner RA. Effect of sildenafil in patients with ED taking antihypertensive medications. *Am J Hypertens* 2001;14:70–73.).

Koyal SN, Whipp BJ, Huntsman D, et al ., Ventilatory responses to the metabolic acidosis of treadmill and cycle ergometry. *J Appl Physiol* 1976;40:864–867.)

Krowka MJ, Swanson KL, Frantz RP et al., Portopulmonary hypertension: results from a 10-year screening algorithm. *Hepatology* 2006; 44: 1502–10.

L. Gullestad, C. Manhenke, T. Aarsland, et al., Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure—substudy to the MERIT-HF trial, *Eur J Heart Fail* 3 (2001), pp. 463–468.

L.E. Rohde, L. Beck da Silva, L. Goldraich, et al., Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure, *Can J Cardiol* 20 (2004), pp. 697–702.

Laties AM, Zrenner E. Viagra® (sildenafil citrate) and ophthalmology. *Prog Ret Eye Res* 2002;21:485–506.).

Lewis T, *Disease of the heart* London:MacMillan,1933).

Libby P: Current concepts of the pathogenesis of the acute coronary syndrome.

Circulation 2001, 104:365-372.).

Lopes-Virella MF, Virella G. Immune mechanism of atherosclerosis in diabetes mellitus. Diabetes 1992; 41 (suppl 2): 86–91.].

Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995, 38:87-104).

Ludmer PL, Selwyn AP, Shook TL, et al ., Paradoxical vasoconstriction induced by acetylcholine in atherosclerosis coronary arteries. N Engl J Med 1986, 315:1046-1051.).

M. Guazzi, G. Tumminello, F.D. Marco, et al ., The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure, J Am Coll Cardiol 44 (2004), pp. 2339–2348).

Mann DL [ed]: Heart Failure: A Companion to Braunwald's Heart Disease.

Philadelphia, Elsevier, 2004. Modified from Sawyer DB, Siwik DA, Xiao L, et al: Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 34:379, 2002.).

Mann DL, Bristow MR: Mechanisms and models in heart failure: The biomechanical model and beyond. Circulation 2005; 111:2837 .

McGoon M, Guttermann D, Steen V et al., Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence- based clinical practice guidelines. Chest 2004; 126 (1 Suppl.): 14S–34.).

McGoon M, Guttermann D, Steen V et al., Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence- based clinical practice guidelines. Chest 2004; 126 (1 Suppl.): 14S–34.

Mercuri F, Quagliaro L, Ceriello A. Oxidative stress evaluation in diabetes. Diabetes Technol Ther 2000; 2: 589–600.].

Miura H, Watchel RE, Liu Y, et al ., Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. *Circulation* 2001, 103:1992-1998.).

MosterdA Hoes AW clinical epidemiology of heart failure 2007 ,93, 1137- 1146)

Mueller C, Laule-Kilian K, Scholer A, et al ., Use of B-type natriuretic peptide for the management of women with dyspnea. *Am) Cnr dial* 2004;94:1510-1514.

Mueller X, Stauffer JC, Jaussi A, et al ., Subjective visual echocardiographic estimate of left ventricular ejection fractions as an alternative to conventional echocardiographic methods: comparison with contrast angiography. *Clin Cardiol* 1991;14:898-902.

N. Galie, H.A. Ghofrani, A. Torbicki, et al., Sildenafil citrate therapy for pulmonary arterial hypertension (for the Sildenafil Use in Pulmonary Arterial Hypertension “SUPER” Study Group), *N Engl J Med* 353 (2005), pp. 2148–2157¹.

Nicholas Hill, MD. Therapeutic Options for the Treatment of Pulmonary Hypertension., 09/08/2005.

Nickening G, Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis. Part I: oxidative stress and atherogenesis. *Circulation* 2002, 105:393-396.].

Nieminen MS, Böhm M, Cowie MR, et al., "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology". *Eur. Heart J.* 26 (4): 384–416.¹. (February 2005).

Nishikawa T, Sasahara T, Kiritoshi S et al., Evaluation of 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. *Diabetes Care* 2003; 26: 1507–12.

Nurnberg HG, Hensley PL, Gelenberg AJ, et al ., Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial controlled trial ". JAMA 289 (1): 56–64. PMID 12503977.

Nurnberg HG, Hensley PL, Lauriello J, et al ., (August 1999). "Sildenafil for women patients with antidepressant-induced sexual dysfunction". *Psychiatr Serv* 50 (8): 1076–8. PMID 10445658.

Nurnberg HG, Hensley PL, Heiman JR, et al ., "Sildenafil Treatment of Women With Antidepressant-Associated Sexual Dysfunction". JAMA 300 (4): 395-404. (2008).

Owan TE, Redfield MM. Epidemiology of diastolic heart failure. *Prog Cardiovasc Dis* 2005; 47: 320–32.

P. Dall'ago, G. Chiappa, H. Guths , et al ., Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized clinical trial, *J Am Coll Cardiol* 47 (2006), pp. 757–763.

Paulus WJ, Tschope C, Sanderson JE, et al ., How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007;28:2539-2550.

Pennell DJ, Sechtem UP, Higgins CB, et al ., Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report.) *Cardiovasc Magn Reson* 2004; 6:727-765.).

Peterson K "Young men add Viagra to their drug arsenal", *USAToday*. (2001-03-21).

pfizer labs 2007).

Pfizer, Inc. "FDA Approves Pfizer's Revatio as Treatment for Pulmonary Arterial Hypertension". 2005 News Releases. Pfizer. Retrieved on December 27, 2005.

Piconi L, Quagliaro L, Ceriello A. Oxidative stress in diabetes. Clin Chem Lab Med 2003; 41: 1144–9.].

Pomeranz HD and Bhavsar AR "Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases". J Neuroophthalmol 25 (1): 9–13. PMID 15756125. (2005).

poole- wilson PA. History,Defintion and classification of heart failure heart failure 1 new yourk: Churchill livingstone,1997.p269-277).

Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal 2001;22:1527–60.

Rich S, Dantzker DR, Ayres SM, et al., Primary pulmonary hypertension. A national prospective study.Ann Intern Med 1987; 107: 216–23.

Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.

Rich S, Rubin LJ, Abenhail L ,et al., Executive summary from the World Symposium on Primary Pulmonary Hypertension (Evian, France, September 6–10, 1998).

Richalet JP, Gratadour P, Robach P, et al ., "Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension". Am. J. Respir. Crit. Care Med. 171 (3): 275–81. doi:10.1164/rccm.200406-804OC. PMID 15516532. .,(2005).

Ridker PM, Brown NJ, Vaughan DE et al., Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109: IV-6–19.].

Roger Clemens, host of athletes pop Viagra to help onfield performance". New York Daily News (2008-06-10).

Rubanyi GM: The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993, 22(Suppl 4):S1-S14

Rudarakanchana, N; Trembath RC, Morrell NW "New insights into the pathogenesis and treatment of primary pulmonary hypertension". Thorax 56 (11): 888–890. PMID 11641516. (November 2001).

Rumberger JA, Behrenbeck T, Bell MR, et al., Determination of ventricular ejection fraction: a comparison of available imaging methods. The Cardiovascular Imaging Working Group. Mayo Clin Proc 1997;72: 860-70.) .

Ruoslatti E. Integrins. J Clin Invest 1991; 187: 1–5.].

S.D. Katz, K. Hryniewicz, I. Hriljac, et al., Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure, *Circulation* **111** (2005), pp. 310–314

Sam F, Sawyer DB, Xie Z, et al., Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 2001; 89:351. ¹.

Sawyer DB, Siwik DA, Xiao L, et al., Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002; 34:379.¹.

Schachinger V, Zehier AM. Prognostic implication of endothelial dysfunction: does it mean anything? Coron Artery Dis 2001; 12: 435–43].

Scharf SM, Iqbal M, Keller C et al., Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314–22.).

Schaufelberger M, Swedberg K, Koster M, et al . DECREASING ONE YEAR MORTALITY and hospitalization rate for heart failure in Sweden , data from Swedish hospital discharge registry 1988 – 2000 . European Heart Journal 2004.25, 300- 307)

Scherrer-Crosbie M, Ullrich R, Bloch KD, et al., Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. *Circulation* 2001; 104:1286.

Senni M , Tribouilloy CM, Rodeheffer RJ, et al ., congestive heart failure in community , trends in incidence and survival in a 10 years period .*Arch internal medicine* 1999,159 ,29-34) .

Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. *American Family Physician* . 2000;61:1319–28.).

Siegel-Itzkovich J. "Viagra makes flowers stand up straight". *Student BMJ* (9). (1999)

Simonneau G, Galiè N, Rubin LJ, et al., "Clinical classification of pulmonary hypertension". *J. Am. Coll. Cardiol.* 43 (12 Suppl S): 5S–12S.
doi:10.1016/j.jacc.2004.02.037. PMID 15194173.
http://content.onlinejacc.org/cgi/content/full/43/12_Suppl_S/5S.1.

Siragy H: Angiotensin II receptor blockers: review of the binding characteristics. *Am J Cardiol* 1999, 84(Suppl):3-8.

Sitbon O, Humbert M, Jais X et al., Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation* 2005; 111: 3105–11.

Stamler JS, Loh E, Roddy Ma, et al ., Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. *Circulation* 1994;89:2035– 40.),

Stevens D, Elpern E, Sharma K, et al ., . Comparison of hallway and treadmill six minute walk tests. *Am J Respir Crit Care Med* 1999;160:1540–1543)

Stewart S,Jenkins A, Buchan S, et al ., the current cost of heart failure to the national health services in U.K. *EUR.J HEART FAILURE* 2002,4,361 – 371)

Stewart S, MacIntyre K, Hole DJ, et al ., more malignant than cancer ? five year survival following a first admission for heart failure ,*EUR.J. HEART FAILURE* 2001;3, 315- 322)

Sun XG, Hansen JE, Oudiz RJ et al., Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 2001; 104: 429–35.)

Sun XG, Hansen JE, Oudiz RJ et al., Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. *Circulation* 2002; 105: 54–60.

Swain DP. Energy cost calculations for exercise prescription: an update. *Sports Med* 2000;30:17–22.)

Swedberg K, Cleland J, Dargie H, et al ., Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. *Eur Heart J* 2005;26: 1115-1140.

Terrett NK "Sildenafil (Viagra), a potent and selective inhibitor of Type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction". *Bioorg Med Chem Lett* 6: 1819–1824. doi:10.1016/0960-894X(96)00323-X. **(1996).**

Timmermans PB, Wong PC, Chiu AT, et al., Angiotensin II receptors and angiotensin II receptor antagonists. *Pharmacol Rev* 45:205, 1993.).

Tomasian D, Keaney JF, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. *Cardiovasc Res* 2000; 47: 426–35].

Topol and Marso , manual of cardiovascular medicine ,2nd edition p. 101

Torre-Amione G, Kapadia S, Lee J, et al ., Expression and functional significance of tumor necrosis factor receptors in human miocardium. *Circulation* 1995, 92:1487-1493.

Trow TK, McArdle JR. Diagnosis of pulmonary arterial hypertension. *Clin Chest Med* 2007; 28: 59–73, viii.

Valen G, Yan Z, Hansson GK: Nuclear factor Kappa-B and the heart.

Vardi M, Nini A "Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus". *Cochrane Database Syst Rev* (1): CD002187. (2007) doi:10.1002/14651858.CD002187.pub3. PMID 17253475

von Romberg, Ernst. "Über Sklerose der Lungenarterie" (in German). *Dtsch Arch Klin Med* 48: 197–206] . (1891-1892)

Wang YX, Ficht RM. Vascular stiffness: measurement, mechanism and implications. *Curr Vasc Pharmacol* 2004; 2: 379–84.].

Wasserman K, Hansen JE, Sue DY,et al ., Principles of exercise testing and interpretation: including pathophysiology and clinical applications, 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. xv.)

Webb, D.J.; Freestone, S.; Allen, et al ., "Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.". *Am. J. Cardiol.* 83 (5A): 21C-28C. PMID 10078539. (March 4, 1999).

Weber KT: Aldosterone in congestive heart failure. *N Engl J Med* 345:1689, 2001.

Weisman IM, Zeballos RJ. Cardiopulmonary exercise testing. *Pulm Crit Care Update* 1995.)

William A. Zoghbi and Juan Carlos Plana: Assessement of ventricular systolic function. In: The ultimate echo guide, 2005, 3: 40-55.

Zapol WM, Rimar S, Grillis N, et al ., Nitric oxide and the lung. Am J Respir Crit Care Med 1994;149:1375– 80.).

Zeihner AM, Drexler H, Wollschlaeger H, et al., Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984–92.].

Zile MR, Baicu CF, Gaasch WH. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004; 350: 1953–9.).